Meeting
2015 ASCO Annual Meeting
Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC).
Authors
Jacques Raphael
Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
Jacques Raphael , Inna Y Gong , Sharon Nofech-Mozes , John M. S. Bartlett , Houman Nafisi , Sunil Verma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 556)
DOI
10.1200/jco.2015.33.15_suppl.556
Abstract #
556
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).
First Author: Carmine De Angelis
Poster
2013 ASCO Annual Meeting
Predictive factors for pathologic complete response (pCR) to trastuzumab(T)-based neoadjuvant chemotherapy in HER2+ breast cancer (BC) women treated in the National Cancer Institute (NCI) of Mexico.
First Author: Erika Sifuentes
Poster
2013 ASCO Annual Meeting
PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.
First Author: Maria Vidal